Meridian says no to Gull at $3 a share:
This article was originally published in Clinica
Executive Summary
Meridian Diagnostics has lowered its earlier offer of $3 a share for Fresenius subsidiary Gull Laboratories, based on Gull's results for the second quarter. According to Gull's president and CEO, Dr Silke Humberg, Meridian, Gull and Fresenius are still willing to complete the deal and are in negotiations to fix a price.